These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24816644)

  • 1. Trajectory and risk factors for chemotherapy-induced nausea and vomiting in Asian patients with head and neck cancer.
    Chan A; Shwe M; Gan Y; Yap K; Chew L; Lim WT
    Head Neck; 2015 Sep; 37(9):1349-57. PubMed ID: 24816644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation.
    Stinson J; Chan K; Lee J; Chow R; Cheon P; Giotis A; Pasetka M; Wan BA; Chow E; DeAngelis C
    Ann Palliat Med; 2017 Aug; 6(Suppl 1):S13-S20. PubMed ID: 28595433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer].
    Fujii M; Ohno Y; Tokumaru Y; Imanishi Y; Kanke M; Kanzaki J
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1095-101. PubMed ID: 9239162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
    Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors that influence the antiemetic activity of metoclopramide to cisplatin based chemotherapy.
    Tsavaris N; Mylonakis N; Bacoyiannis C; Kosmas C; Kalergis G; Iakovidis V; Tzaninis D; Kosmidis P
    Oncol Rep; 1998; 5(5):1147-55. PubMed ID: 9683826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
    Shih V; Wan HS; Chan A
    Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first clinical report.
    Mantovani G; Curreli L; Macciò A; Massa E; Massa D; Mulas C; Succu G; Contu P
    Anticancer Res; 1999; 19(4C):3495-502. PubMed ID: 10629642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC).
    Schwartzberg L; Szabo S; Gilmore J; Haislip S; Jackson J; Jain G; Balu S; Buchner D
    Curr Med Res Opin; 2011 Apr; 27(4):837-45. PubMed ID: 21309647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Low-dose CDDP and 5-FU for head and neck cancer patients].
    Fujii M; Kanke M; Tomita T
    Gan To Kagaku Ryoho; 1999 Oct; 26(11):1542-7. PubMed ID: 10553410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiemetic effectiveness and nausea and vomiting incidence during capecitabine and oxaliplatin chemotherapy.
    Chan A; Tan SH; Low XH; Yap KY
    Nurs Res; 2012; 61(6):405-12. PubMed ID: 22960588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer.
    Kohno N; Ichikawa G; Shirasaka T; Inuyama Y; Kawaida M; Ohnuma T
    Gan To Kagaku Ryoho; 1995 Aug; 22 Suppl 3():209-14. PubMed ID: 7661582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
    Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
    J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
    Kohno N; Kitahara S; Tamura E; Tanabe T; Nakanoboh M; Kawada M; Shirasaka T
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():592-9. PubMed ID: 10895216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck.
    Rades D; Kronemann S; Meyners T; Bohlen G; Tribius S; Kazic N; Schroeder U; Hakim SG; Schild SE; Dunst J
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1037-44. PubMed ID: 20638185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cancer-related fatigue on chemotherapy-induced nausea and vomiting in Asian cancer patients.
    Poon KS; Un MK; Low XH; Cheung YT; Yap KY; Chan A
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1345-51. PubMed ID: 24023040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
    Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA;
    J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous cisplatin and 5-fluorouracil as second-line treatment of head and neck cancer.
    Merlano M; Grimaldi A; Brunetti I; Modenesi M; Scala M; Margarino G; Scasso F; Santelli A; Castiglia G; Pallestrini E
    Cancer Treat Rep; 1987 May; 71(5):485-8. PubMed ID: 3567974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
    Cheirsilpa A; Ratanatharathorn V; Sinlarat P; Chindavijak K; Lousoontornsiri W; Chakrapee-Sirisuk S; Srimuninimit V
    J Med Assoc Thai; 1994 Apr; 77(4):201-6. PubMed ID: 7844494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres.
    O'Brien BJ; Rusthoven J; Rocchi A; Latreille J; Fine S; Vandenberg T; Laberge F
    CMAJ; 1993 Aug; 149(3):296-302. PubMed ID: 8339175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.